Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI WW FrankfurtCPhI WW Frankfurt
Not Confirmed
Not Confirmed
28-30 October, 2025
Not Confirmed
Not Confirmed
04-06 September, 2025
Not Confirmed
Not Confirmed
08-11 September, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI WW FrankfurtCPhI WW Frankfurt
Industry Trade Show
Not Confirmed
28-30 October, 2025
Industry Trade Show
Not Confirmed
04-06 September, 2025
Industry Trade Show
Not Confirmed
08-11 September, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/50-years-of-innovation-mikart-s-legacy-and-what-s-next-in-cdmo-excellence
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/fda-approvals-drop-24-in-h1-2025-gsk-s-uti-med-vertex-s-non-opioid-painkiller-lead-pack-of-first-in-class-meds
25 Aug 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/thryv-therapeutics-to-present-at-the-2025-european-society-of-cardiology-congress-in-madrid-spain-302537792.html
13 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/thryv-therapeutics-to-share-recent-clinical-results-and-participate-in-upcoming-healthcare-investor-conferences-302453094.html
18 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/thryv-therapeutics-to-attend-the-2025-jp-morgan-healthcare-conference-in-san-francisco-302334932.html
04 Nov 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/thryv-therapeutics-to-sponsor-and-participate-in-the-2024-international-sads-foundation-family-conference-in-chicago-302294880.html
15 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/thryv-therapeutics-receives-positive-top-line-results-from-wave-i-part-2-clinical-study-in-long-qt-syndrome-type-2-and-type-3-patients-302275785.html
01 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/thryv-therapeutics-granted-fda-orphan-drug-designation-for-lqt-1213-in-long-qt-syndrome-treatment-302263979.html
ABOUT THIS PAGE